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Background and aim: Angiogenesis is an important process in the pathogenesis of chronic inflammation.
We aimed to study the angiogeneic balance in inflammatory bowel disease (IBD) by evaluating the expression
of vascular endothelial growth factor (VEGF) and thrombospondin-1 (TSP-1) on colonic epithelial cells,
together with the expression of inducible nitric oxide synthase (iNOS).
Methods: Twenty-one ulcerative colitis (UC), 14 Crohn’s disease (CD), 11 colorectal cancer patients, and
11 healthy controls colonic biopsy samples were evaluated immunohistochemically.
Results: The expressions of TSP-1, VEGF, and iNOS in UC and CD groups were higher than expression in
healthy control group, all with statistical significance. However, in colorectal cancer group, VEGF and iNOS
expressions were increased importantly, but TSP-1 expression was not statistically different from healthy
control group’s expression. Both TSP-1 and VEGF expressions were correlated with iNOS expression
distinctly but did not correlate with each other.
Conclusions: Both pro-angiogeneic VEGF and antiangiogeneic TSP-1 expressions were found increased in
our IBD groups, but in colorectal cancer group, only VEGF expression was increased. TSP-1 increases in IBD
patients as a response to inflammatory condition, but this increase was not enough to suppress pathologic
angiogenesis and inflammation in IBD.
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I
nflammatory bowel disease (IBD) is a chronic
intestinal disorder with an unknown etiology. IBD
presents mainly in two forms: ulcerative colitis (UC)
or Crohn’s disease (CD). A wide list of environmental,
genetic and immunologic factors can trigger an uncon-
trolled immune response in genetically predisposed
individuals, which leads to chronic inflammation within
the intestinal wall (1). This uncontrolled or inappropri-
ately regulated immune system activation can cause
sustained overproduction of reactive metabolites of
oxygen and nitrogen, which was one of the mechanisms
of intestinal injury and dysfunction observed in IBD (2).
Nitric oxide is one of the major reactive species mainly
produced in the intestines by the enzyme inducible nitric
oxide synthase (iNOS). Especially, neutrophils and
macrophages that contribute to the colitis generate
reactive oxygen and nitrogen species (35).
The role of the non-immune cells, including endothelial
cells, in the pathogenesis of IBD has long been recog-
nized. So, not only the classical immune system elements
(i.e. T and B lymphocytes, macrophages, and dendritic
cells) but also vascular endothelial cells play important
roles in triggering chronic and uncontrolled inflammation
within the intestinal wall (6, 7). There is a continuous
epithelial regeneration in the intestinal mucosa of the
patients with IBD. In an inflamed mucosa, the need for
nutrients and oxygen as well as the amounts of the waste
products increases. For the maintenance of this circuit,
formation of new blood vessels from the old ones was
required, which is called angiogenesis (8).
The formation of new vessels (angiogenesis) is con-
trolled by the balance between pro- and antiangiogenic
molecules. Under normal conditions, intestinal damage is
followed by a physiological angiogenesis for promoting
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abnormal expression of some pro- and antiangiogenic
molecules. So, the new balance between pro- and anti-
angiogenic molecules could cause a different or patholo-
gical vascular remodeling, which may favor and maintain
the chronic inflammation seen in IBD (8, 9).
Angiogenesis is controlled by a complex network of
activators and inhibitors. Between the wide list of factors
playing a role in the angiogenesis, vascular endothelial
growth factor (VEGF) was the major rate-limiting step
during the process (7). VEGF is a potent angiogenic and
vascular permeability-enhancing cytokine with overex-
pression during tissue repair processes, chronic inflam-
mation, and tumoral growth (911). Thrombospondins
(TSPs) are a family of secreted glycoproteins that play an
important role in the maintenance of the structure of the
extracellular matrix and the regulation of the cellular
phenotype. Among the five subtypes in the TSP family,
TSP-1 has significant antiangiogenic effects. Also, TSP-1
is involved in clotting, proliferation, cell attachment, and
motility (12, 13). There are a lot of articles in the
literature showing increased VEGF in IBD. But, there
are a few inconclusive studies for TSP-1 in IBD. We
aimed to investigate the angiogenic balance in IBD by
evaluating the expression of VEGF and TSP-1 on colonic
epithelial cells, together with the expression of iNOS.
Materials and methods
The study included 21 patients with UC (11 male, age:
40.8915.2) and 14 patients with CD (7 male, age: 32.49
13.1). Also, 11 patients with adenocarcinoma of the
colon: colon cancer (CC) (6 male, age: 62.498.3) were
included in the study as diseased control. The formalin-
fixed paraffin-embedded tissue samples of sporadic (non-
familial, non-IBD related) CC patients were obtained
from our hospital pathology archive. Otherwise, healthy
persons referred for screening with completely normal
colonoscopy were used as healthy controls (11 persons,
5 male, age: 44.2910.6). Consecutive IBD outpatients of
our gastroenterology clinic were enrolled into the study.
All the IBD patients had a definitive diagnosis of CD or
UC confirmed by clinical, radiological, endoscopic, and
histological findings. Disease activity in patients with CD
and UC was assessed by Saverymuttu et al.’s method (14),
and patients having grade-1 histological activity were
excluded from the study. Also, patients using any other
medication other than mesalasine and/or antibiotic in the
last 6 months were not enrolled into the study.
Immunohistochemistry: as primary antibodies, mouse
monoclonal antibody that recognizes VEGF (Ab-7, clone
VG1: Lab vision, 1/100, Westinghouse, CA), rabbit
polyclonal antibody that recognizes iNOS (Ab1: Lab
vision, 1/100, Westinghouse, CA), mouse monoclonal
antibody that recognizes TSP-1 (Ab-4, clone A6.1: Lab
vision, 1/100, Westinghouse, CA) were used.
Immunoperoxidase studies were performed on 4-mm-
thick paraffin-embedded sections of formalin-fixed tissue
samples. Immunohistochemical staining was performed
using the streptavidinbiotin method. Briefly, the sections
were deparaffinized with xylene for 10 min, rehydrated
through a graded series of ethyl alcohol for 30 min, and
immersed in 0.3% hydrogen peroxide in methanol for
20 min to block endogenous peroxidase activity. Then,
the sections were washed with distilled water. Antigen
retrieval was performed in citrate buffer (0.01 M, pH: 6.0)
for TSP-1 and iNOS and in ethylenediaminetetraacetic
acid (EDTA, 1 mM, pH: 8.0) for VEGF by microwave
treatment. The sections in citrate buffer or EDTA were
incubated at high temperature for 5 min and then at
medium temperature for 15 min. Then, the sections were
washed with phosphate-buffered saline (PBS pH: 7.6,
1:100) for 5 min. After that, they were placed in goat
antipolyvalent immunoglobulin (1:100) for 10 min and
then washed with PBS three times. The sections were
incubated with primary antibodies for 1 h at room
temperature, followed by three washes with PBS for 3
5 min. Then, the sections were treated with biotin reagent
for 20 min and avidin reagent for 20 min and washed
again with PBS for 25 min. Finally, specimens were
treated with a mixture of 3-amino-9-ethylcarbazole
(AEC, Thermo Scientific, Fremont, CA, USA) buffer
and AEC chromogen and counterstained with hematox-
ylin. Then, they were washed, dehydrated and mounted
with aqueous material for examination. The examination
of the slides was done in a blinded manner.
Expression of the VEGF, iNOS, and TSP-1 were
observed in the cytoplasm and/or membranes of
the epithelial cells. The most prominent staining areas
were evaluated for all sections. A semi-quantitative
‘staining index’ was assessed as first described by King
et al. (15) and then by others (9, 16, 17). First, the
staining distribution and staining intensity were evalu-
ated. The staining extent (or distribution) of iNOS,
VEGF, and TSP-1 was assessed as percentage of posi-
tively stained cells among 1,000 cells and classified into
15 categories (1: 05%; 2: 625%; 3: 2650%; 4: 5175%;
5: 76100%). Staining intensity was graded as weak
(1: ), moderate (2:), and strong (3:) using
an arbitrary scale. And, finally the ‘staining index’ was
calculated by adding the score of percentage expression
to the intensity of staining. For example, the ‘staining
index’ of a patient having 40% (means 3)  (means 2)
staining was (325) five.
Statistical method: all statistical tests were done using
SPSS 13 software. For non-parametric values, Kruskal
Wallis test and for parametric values one-way Anova and
t-test were used. For correlation, Pearson correlation test
was used. Statistical significance was set as p values lower
than 0.05.
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While evaluating demographic features of the study
groups, the mean age of CC group was found signifi-
cantly higher than the other three groups. Other features
were similar. Two of the UC patients’ Saverymuttu score
was 2 and the remaining 19 patients’ score was 3. Five of
the CD patients’ Saverymuttu score was 2 and the
remaining nine patients score was 3. Mean disease time
was 4.996.5 years for UC group and 2.791.7 years for
CD group. Nine of the UC patients had extensive or
pancolitis, four patients had left-sided colitis, and eight
patients had distal colitis. Only one of the UC patients
had CC in the past. We studied both colitis and cancer
tissues of this patient. Eight of the CD patients had
ileocolonic disease and the remaining six patients had
colonic disease.
Immunohistochemistry results (staining index) of the
groups are shown in Table 1. The expression of TSP-1 on
colonic epithelial cells was detected as a cytoplasmic
staining (Fig. 1). The expression of TSP-1 of both UC
and CD groups was higher than the healthy control group
statistically (p0.004, p0.029, respectively). TSP-1
expression of CC group was intermediate between the
IBD groups and healthy control group values and no
statistical difference was detected. The highest expression
of TSP-1 was detected in UC group, but it was not
different from CD group. In UC group, we had a female
patient with a history of 30 years of pancolitis who
developed CC. Interestingly, we did not find the expres-
sion of TSP-1 on CC and other colon tissues of this
patient.
The expression of VEGFon colonic epithelial cells was
also detected as a cytoplasmic staining (Fig. 2). The
expression of VEGF was lowest in healthy control group.
Also, UC, CD, and CC groups had increased VEGF
expressions relative to healthy control group’s expression,
with statistical significance (p0.001). But, there was not
a difference between these three groups for the expression
of VEGF.
We could not find the expression of iNOS in healthy
control group’s tissues. All three disease groups’ tissues
demonstrated both cytoplasmic staining and borderline
pattern on the apical surface of epithelium (Fig. 3). UC,
CD, and CC groups had significantly higher iNOS
expression than healthy control group (p0.001). But,
the expressions of iNOS of these three groups were close
to each other. However, CC group had lower expression
of iNOS than IBD group.
Expression of TSP-1, iNOS, and VEGF was not
different between UC and CD groups. CC group’s
expressions were not different from IBD groups, statisti-
cally. The expressions of TSP-1, VEGF, and iNOS in UC
and CD groups were higher than expressions of healthy
control group, all with statistical significance. However, in
the CC group, VEGF and iNOS expressions were
increased importantly, but TSP-1 expression was not
statistically different from healthy control group’s expres-
sion. Both TSP-1 (r: 0.650, pB0.01) and VEGF (r: 0.397,
Table 1. Table showing thrombospondin-1 (TSP-1), vascular
endothelial growth factor (VEGF), and inducible nitric
oxide synthase (iNOS) expressions (staining index) of the
study groups
TSP-1 VEGF iNOS
Ulcerative colitis 3.9192.1* 3.9592.5* 6.2992.1*
Crohn’s disease 3.8692.4** 4.1492.0* 6.4391.8*
Colorectal cancer 3.0991.9 3.4591.8* 5.7392.5*
Healthy control 2.2090.9 0.5790.9 0.00
*pB0.005 according to healthy control, **pB0.05 according to
healthy control.
Fig. 1. Thrombospondin-1 expression in the cytoplasm of
the colonic epithelium (100).
Fig. 2. VEGF expression in the cytoplasm of the colonic
epithelium (200).
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sion distinctly but did not correlate with each other.
No relation between these VEGF, TSP-1, and iNOS
expressions and IBD patient’s age, sex, disease time,
histological activity, and disease location could be
demonstrated.
Discussion
Active inflammation of the colonic mucosa was asso-
ciated with an increased production of tissue-derived
cytokines, such as tumor necrosis factor-a (TNF-a),
interleukin-1-b, and interferon-g, that are capable of
inducing iNOS in enterocytes, neutrophils, and endothe-
lial cells. Thus, the induction of iNOS in intestinal
epithelial cells may represent a pathway for intestinal
damage (18). The expression of iNOS on colonic
epithelial cells and its relation with immunomodulatory
cytokines were demonstrated in previous studies in IBD
(19, 20). In the present study, we did not find iNOS
expression on the normal mucosa of healthy control
group. Kolios et al. (21) did not demonstrate the
expression of iNOS on normal mucosa. However,
Roberts et al. (22) reported that iNOS was often
expressed in the surface epithelium of non-inflamed
human colon. In our study, we showed increased expres-
sion of iNOS in IBD groups and CC group. This finding
was correlated with the previous reports. But, our IBD
groups’ iNOS expression was not correlated with the
histological activity. We thought that these data were due
to excluding IBD patients with Saverymuttu’s grade-1
mild colitis. On the other hand, iNOS expression
correlated both with VEGF and TSP-1 expressions in
our study. It is known that NO and iNOS have both anti-
inflammatory and proinflammatory properties that are
important in the pathogenesis of IBD (23). Our study
supports this possible double effect of iNOS in IBD.
Thrombospondin-1 is the best-known molecule among
antiangiogenic agents. TSP-1 was frequently studied for
invasion, metastasis, and prognosis of malignancies,
including ovarian cancer (24), gastric cancer (25), breast
carcinoma (26), lung cancer (27), renal cell carcinoma
(28), and pancreatic cancer (29). These studies demon-
strated that low or absent expression of TSP-1 is
associated with advanced stage cancer. Also, it was
reported that decreased expression of TSP-1 was corre-
lated with poor prognosis in colorectal carcinoma (13,
3032). There are a few articles in the literature dealing
with the role of TSP-1 in IBD. Zak et al. (12) studied
TSP-1-deficient mice with experimental colitis, and they
suggested that TSP-1 might decrease angiogenesis. We
found that the expression of TSP-1 was higher in IBD
groups relative to healthy control group. Also, our CC
group’s TSP-1 expression is intermediate between the
IBD groups and HC group values, without any statistical
difference. Jo et al. (13) demonstrated that TSP-1 was
strongly expressed in normal colonic epithelial cells. Also,
they showed that the loss of TSP-1 was observed in early
colonic adenomas and it became undetectable in invasive
CCs. We demonstrated the expression of TSP-1 in healthy
control group, but CC group’s TSP-1 expression,
although it is not statistically important, was somewhat
higher than that in the healthy control group. In our
study, the expression of TSP-1 was not lost or down-
regulated in CC. However, both colitis and cancer tissue
of the only patient who developed CC during the course
of her UC had no expression of TSP-1. We did not find
difference between UC and CD groups. TSP-1 may have
different functions in cell proliferation, apoptosis, angio-
genesis inhibition, cell attachment, and motility. TSP-1
modulates the immune system, via binding and activating
transforming growth factor-b1. It was reported that
chronic inflammatory conditions have high expressions
of TSP-1 (33). We suggest that TSP-1 increases in IBD
patients as a response to inflammatory condition, but
this increase was not enough to suppress pathologic
angiogenesis and inflammation in IBD.
Vascular endothelial growth factor is a well-known
pro-angiogenic factor. It also increases vascular perme-
ability, stimulates leukocyte adhesion to the endothelium,
and promotes monocyte chemotaxis. VEGF is found
increased in IBD patients’ tissue and sera (9, 10, 34, 35).
In our study, we found that the expression of VEGF was
increased in IBD groups relative to healthy control
statistically. Also, CC group had significantly higher
VEGF expression than healthy control group. These
findings are compatible with the literature. Griga et al.
(34) reported that the expression of VEGF was higher in
active IBD patients than inactive IBD patients. We found
no correlation between VEGF expression and disease
activity in our previous (9) and the present studies.
Fig. 3. iNOS expression in the cytoplasm and the apical
surface of the colonic epithelium (200).
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VEGF-induced human angiogenesis both by the displa-
cement of VEGF from endothelial cell heparan sulfate
and by direct binding to VEGF. Maeda et al. (37) studied
VEGF and TSP-1 together in CC. They demonstrated
that TSP-1 was correlated with good prognosis and
VEGF was correlated with worse prognosis. Inflamma-
tory tissue is often hypoxic, and hypoxia is an important
pro-angiogenic stimulus, acting through upregulation of
factors such as VEGF, fibroblast growth factor, TNF-a,
hypoxia-inducible factor-1, and other factors (38). VEGF
is demonstrated to play a master role in angiogenesis and
inflammation and regulates immune-driven angiogenesis
in IBD (39, 40). TSP-1 may be a protective factor and
may inhibit pathological angiogenesis in IBD. As re-
ported previously, recombinant TSP-1 or mimetic peptide
ABT-510 may decrease angiogenesis and inflammation
and may be a new therapeutic approach in IBD (41, 42).
Angiogenesis is an important process in IBD. In our
study, the expression of iNOS increased and correlated
with VEGF and TSP-1. Both pro-angiogeneic VEGF and
antiangiogeneic TSP-1 expressions were found increased
in our IBD groups, but in CC group only VEGF
expression was increased. Angiogenesis, immune-driven
angiogenesis, or pathologic angiogenesis is a complex
process that possibly includes multiple pathways and
molecules. More advanced studies dealing with this issue
will give important information about the pathogenesis of
IBD and offer new therapeutic options to us.
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